
Centogene N.V. CNTG
Annual report 2023
added 12-27-2025
Centogene N.V. General and Administrative Expenses 2011-2026 | CNTG
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Centogene N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 46.7 M | 37.7 M | 30.4 M | 26.1 M | 9.5 M | 8.89 M | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46.7 M | 8.89 M | 26.6 M |
Quarterly General and Administrative Expenses Centogene N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 7.91 M | - | 10.4 M | 10.5 M | 11.6 M | - | 8.37 M | 7.77 M | 7.9 M | - | 4.88 M | 5.69 M | 5.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | 4.88 M | 8.09 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Interpace Biosciences
IDXG
|
9.49 M | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
Illumina
ILMN
|
1.09 B | $ 123.79 | -0.43 % | $ 19.7 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.13 | -2.74 % | $ 4.89 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 25.75 | 3.0 % | $ 715 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
NeoGenomics
NEO
|
273 M | $ 8.1 | 1.76 % | $ 1.04 B | ||
|
Exact Sciences Corporation
EXAS
|
889 M | $ 104.91 | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
54.8 M | $ 17.51 | 1.1 % | $ 392 M | ||
|
Natera
NTRA
|
589 M | $ 200.09 | 2.46 % | $ 19.7 B | ||
|
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
14.3 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
OPKO Health
OPK
|
304 M | $ 1.15 | 2.68 % | $ 798 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Personalis
PSNL
|
46.2 M | $ 7.61 | 4.82 % | $ 451 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 158.0 | 2.86 % | $ 7.83 B | ||
|
IQVIA Holdings
IQV
|
2 B | $ 166.96 | 0.54 % | $ 28.7 B | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 75.73 | -0.92 % | $ 5.11 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
IDEXX Laboratories
IDXX
|
405 M | $ 578.51 | 0.22 % | $ 46.5 B | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
51.9 M | $ 1.46 | 26.96 % | $ 1.86 M | ||
|
Medpace Holdings
MEDP
|
198 M | $ 456.93 | 0.98 % | $ 13.2 B | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 6.62 | 2.16 % | $ 276 M | ||
|
Sotera Health Company
SHC
|
253 M | $ 13.88 | 2.81 % | $ 3.94 B | ||
|
Agilent Technologies
A
|
1.62 B | $ 112.02 | 0.65 % | $ 34.1 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 100.35 | 0.65 % | $ 8.28 B | ||
|
Soleno Therapeutics
SLNO
|
132 M | $ 31.72 | -4.52 % | $ 1.61 B | ||
|
DarioHealth Corp.
DRIO
|
15.2 M | $ 7.5 | -6.13 % | $ 29.9 M | ||
|
Guardant Health
GH
|
211 M | $ 84.9 | -0.33 % | $ 10.6 B | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.66 | 1.75 % | $ 432 M | ||
|
Psychemedics Corporation
PMD
|
7.19 M | - | -1.84 % | $ 15.3 M | ||
|
Neuronetics
STIM
|
31.5 M | $ 1.6 | 10.34 % | $ 106 M | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Mettler-Toledo International
MTD
|
998 M | $ 1 239.07 | 2.87 % | $ 25.5 B | ||
|
CareDx, Inc
CDNA
|
108 M | $ 17.56 | 2.39 % | $ 936 M | ||
|
ENDRA Life Sciences
NDRA
|
7.06 M | $ 3.48 | 0.87 % | $ 1.87 M | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 478.12 | 0.79 % | $ 180 B | ||
|
Celcuity
CELC
|
9.06 M | $ 106.75 | 0.67 % | $ 4.21 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 264.42 | 0.54 % | $ 22 B |